Review summarizes advances in single-cell RNA sequencing and its role in viral infection research, highlighting immune and pathogen interactions.
Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology in infectious disease research, enabling high-resolution characterization of cellular heterogeneity, immune dynamics, and host-pathogen interactions at the single-cell level. In the context of viral infections-including SARS-CoV-2, hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza virus, and respiratory syncytial virus (RSV)-scRNA-seq has provided critical insights into immune-cell heterogeneity, immune landscape remodeling, and the emergence of previously unrecognized cellular states. Beyond immune profiling, scRNA-seq enables direct detection of viral transcripts within infected cells. This allows discrimination between productively infected and bystander cells and reveals virus-induced transcriptional reprogramming within target tissues.. Additionally, single-cell approaches facilitate the analysis of adaptive immune repertoires through integrated integrated T-cell receptor (TCR) and B-cell receptor (BCR) sequencing sequencing and uncover intra-host viral diversity and evolutionary dynamics at unprecedented resolution. This review summarizes recent advances in the application of scRNA-seq in viral infection research, with a focus on immune regulation, host-pathogen co-transcriptomics, inflammatory signaling pathways, biomarker discovery, and translational implications. Comparative single-cell studies across acute and chronic viral infections have further revealed both shared antiviral programs and virus-specific immune adaptations.We further discuss current technical limitations and emerging computational strategies, as well as future integration with spatial transcriptomics and multi-omics platforms. Collectively, these developments highlight the potential of single-cell technologies to advance mechanistic understanding and guide precision diagnostics and therapeutic strategies in viral diseases.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: